Semaglutide e carenza nelle farmacie 2023-2024 Nella prima met del 2023, l'AIFA (l'Agenzia Italiana del Farmaco) ha diramato una nota informativa importante in merito alla carenza del medicinale Ozempic a base di semaglutide in soluzione iniettabile
What theyre saying: We believe that inhibiting new pathways on top of GLP-1 receptor agonism has the potential to achieve comparable overall reductions in body weight, but with improved quality of a weight loss, resulting in more fat loss while preserving or actually increasing muscle mass. Regenerons CSO George Yancopoulos The big picture If any of these medications (or combinations of medications) can actually enable people to lose weight while preserving muscle mass, the impact on public health could be huge but itll likely be years before they reach the market
Membership Cost First month: $39 Renewal: $149 per month Medication: Not included Standard shipping: $5 Laboratory work: Not clearly included as a universal benefit
Original Medicare (parts A and B) does not cover Wegovy because Medicare Part B covers only doctor-administered drugs
If you see marketing language suggesting otherwise, approach those claims with appropriate skepticism
The confusion stems from medication approval pathways